Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-02-10Clinical Trial Update: Stepped Care for Depression in Heart Failure [NA]
A completed clinical trial evaluating stepped care for depression in patients with heart failure; results posted in 2023.
-
CLINICAL_TRIALS withdrawal · 2023-02-09Clinical Trial Update: Optimal Duration of Olanzapine Add-on Therapy in Major Depression [Phase 3]
A Phase 3 trial evaluating the optimal duration of add-on olanzapine therapy in major depressive disorder was withdrawn.
-
FDA approval · 2023-02-08FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (CIPLA USA INC.,)
FDA approved a supplemental application for Bupropion hydrochloride submitted by Cipla USA Inc., reflecting a regulatory action on an existi…
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Ketamine for Older Adults Pilot [Phase 4]
Pilot Phase 4 trial investigating ketamine for treatment resistant depression in older adults has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression [Phase 2]
Phase 2 clinical trial of intravenous ganaxolone in women with postpartum depression has completed and results were posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: The Influence of Probiotic Supplementation on the Severity of Anxiety and Depressive Symptoms, as Well as the Function and Composition of Gut Microbiota, Metabolic, Inflammation, and Oxidative Stress Markers in Patients With Depression [Phase 2]
Phase 2 clinical trial evaluating the effects of probiotic supplementation on anxiety and depressive symptoms, gut microbiota, metabolic, in…
-
FDA approval · 2023-02-07FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (Cadila Pharmaceuticals Limited)
FDA approved a supplemental application for bupropion hydrochloride submitted by Cadila Pharmaceuticals Limited.
-
FDA approval · 2023-02-07FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
The FDA approved a supplemental application for Bupropion hydrochloride from Heritage Pharmaceuticals (d/b/a Avet Pharmaceuticals Inc.), rep…
-
CLINICAL_TRIALS trial_result · 2023-02-06Clinical Trial Update: Designing a Mental Health Model for Latina Women [NA]
A completed clinical trial focused on designing a mental health model for Latina women, with conditions including Mental Health Wellness 1 a…
-
FDA approval · 2023-02-03FDA Approved: BREXPIPRAZOLE — Original Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA Inc.'s original application for brexpiprazole (brexpiprazole), authorizing a generic version of the antipsych…
-
CLINICAL_TRIALS trial_result · 2023-02-01Clinical Trial Update: Does an Occupational Therapy Program Enhance Mental Health Outcomes for Veterans Who Scuba Dive [NA]
Completed clinical trial evaluating an occupational therapy program for mental health outcomes in veterans who scuba dive, with listed condi…
-
FDA approval · 2023-01-31FDA Approved: ARIPIPRAZOLE — Supplemental Application (VistaPharm, LLC)
FDA approved a supplemental application for aripiprazole filed by VistaPharm, LLC, marking approval of a supplemental submission for this ge…
-
FDA approval · 2023-01-31FDA Approved: PAROXETINE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for paroxetine from ANI Pharmaceuticals, indicating an approved change to the product (e.g., lab…
-
CLINICAL_TRIALS trial_result · 2023-01-30Clinical Trial Update: A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression [Phase 2]
Phase 2 clinical trial of oral ganaxolone in women with postpartum depression has completed with results posted.
-
CLINICAL_TRIALS withdrawal · 2023-01-30Clinical Trial Update: Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety [Phase 4]
Open-label Phase 4 trial of brexpiprazole in adults with major depressive disorder and anxiety was withdrawn.
-
CLINICAL_TRIALS trial_result · 2023-01-26Clinical Trial Update: Rapid Antidepressant Effects of Leucine [Phase 2]
Phase 2 trial investigating rapid antidepressant effects of leucine in adults with major depressive disorder; study terminated with results …
-
FDA approval · 2023-01-25FDA Approved: ZOLOFT — Supplemental Application (ROERIG)
The FDA approved a supplemental application for Zoloft (sertraline hydrochloride) filed by Roerig.
-
CLINICAL_TRIALS trial_result · 2023-01-25Clinical Trial Update: A Problem Solving Intervention for Hospice Caregivers [NA]
Clinical trial on a problem-solving intervention for hospice caregivers has completed with posted results.
-
FDA approval · 2023-01-23FDA Approved: DESVENLAFAXINE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approves a supplemental application for desvenlafaxine succinate from Alembic Pharmaceuticals Limited, enabling the marketing of a gener…
-
FDA approval · 2023-01-18FDA Approved: MIRTAZAPINE — Original Application (Prasco Laboratories)
FDA approved Prasco Laboratories' Original Application for a generic mirtazapine product. Mirtazapine is indicated for the treatment of majo…
-
CLINICAL_TRIALS research · 2023-01-17Clinical Trial Update: RESCUE Stroke Caregiver Website to Enhance Discharge Planning [NA]
Clinical trial about a caregiver website to support discharge planning for stroke care; completed with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-01-13Clinical Trial Update: Mindful Breathing and tDCS for Depression [NA]
A completed clinical trial investigating mindful breathing and transcranial direct current stimulation for depression; results posted in 202…
-
FDA approval · 2023-01-09FDA Approved: BUPROPION HYDROCHLORIDE SR — Original Application (Epic Pharma, LLC)
FDA approved Epic Pharma's generic bupropion hydrochloride sustained-release (BHCl SR) under an Original Application.
-
CLINICAL_TRIALS trial_result · 2023-01-05Clinical Trial Update: Vortioxetine to Prevent Return of Symptoms in Children With Depression [Phase 3]
Phase 3 trial investigating vortioxetine to prevent relapse of depressive symptoms in children with depression; study terminated with posted…
-
CLINICAL_TRIALS trial_result · 2023-01-04Clinical Trial Update: Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder [NA]
A completed clinical trial on maintenance transcranial magnetic stimulation for major depressive disorder has posted results.